Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

STRATA Skin Sciences (SSKN) Shares Outstanding (Diluted Average) (2017 - 2025)

STRATA Skin Sciences' Shares Outstanding (Diluted Average) history spans 11 years, with the latest figure at $4.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 22.15% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 million, a 22.15% increase, with the full-year FY2025 number at $4.7 million, up 22.15% from a year prior.
  • Shares Outstanding (Diluted Average) hit $4.7 million in Q4 2025 for STRATA Skin Sciences, up from $4.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for SSKN hit a ceiling of $34.9 million in Q1 2023 and a floor of $3.5 million in Q2 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $17.6 million across 5 years, with a median of $4.5 million in 2025.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 9252691.85% in 2021 and later tumbled 89.95% in 2023.
  • Tracing SSKN's Shares Outstanding (Diluted Average) over 5 years: stood at $34.1 million in 2021, then grew by 1.94% to $34.7 million in 2022, then tumbled by 89.94% to $3.5 million in 2023, then rose by 9.03% to $3.8 million in 2024, then rose by 22.15% to $4.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SSKN at $4.7 million in Q4 2025, $4.3 million in Q3 2025, and $4.2 million in Q2 2025.